Zobrazeno 1 - 10
of 242
pro vyhledávání: '"Daniel M Sullivan"'
Autor:
Eileen R Grigson, Maria Ozerova, Alexandra Pisklakova, Hao Liu, Daniel M Sullivan, Yulia Nefedova
Publikováno v:
PLoS ONE, Vol 10, Iss 1, p e0117693 (2015)
Canonical Wnt signaling has been implicated in the regulation of multiple myeloma (MM) growth. Here, we investigated whether the targeting of this pathway with a novel pharmacological inhibitor ICG-001 would result in an anti-tumor effect and improve
Externí odkaz:
https://doaj.org/article/b73d2ca360e04feda1b3613cf35a8eb7
Publikováno v:
Journal of the Association of Environmental and Resource Economists. 10:447-486
Autor:
Amit Mahipal, Daniel M. Sullivan, Tami Rashal, Yosef Landesman, Marsha Crochiere, Trinayan Kashyap, Sherma Zibadi, Kazim Husain, Domenico Coppola, Mokenge P. Malafa, Sabiha Kazim
Pancreatic cancer is an aggressive and deadly malignancy responsible for the death of over 37,000 Americans each year. Gemcitabine-based therapy is the standard treatment for pancreatic cancer but has limited efficacy due to chemoresistance. In this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c4de66502442fd1c27771aa463f2097d
https://doi.org/10.1158/1535-7163.c.6536836.v1
https://doi.org/10.1158/1535-7163.c.6536836.v1
Autor:
Amit Mahipal, Daniel M. Sullivan, Tami Rashal, Yosef Landesman, Marsha Crochiere, Trinayan Kashyap, Sherma Zibadi, Kazim Husain, Domenico Coppola, Mokenge P. Malafa, Sabiha Kazim
Supplemental legend for Fig. S1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a88d211814de965f8db6efd60b53e86e
https://doi.org/10.1158/1535-7163.22501585.v1
https://doi.org/10.1158/1535-7163.22501585.v1
Autor:
Amit Mahipal, Daniel M. Sullivan, Tami Rashal, Yosef Landesman, Marsha Crochiere, Trinayan Kashyap, Sherma Zibadi, Kazim Husain, Domenico Coppola, Mokenge P. Malafa, Sabiha Kazim
Supplementary Figure S1. Effect of KPT-330 on human normal pancreatic epithelial (HPNE) cell proliferation (MTT assay).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7065f4e9afb122edc1f64318c116431f
https://doi.org/10.1158/1535-7163.22501588
https://doi.org/10.1158/1535-7163.22501588
Autor:
James H. Doroshow, Richard M. Simon, Barbara A. Conley, Robert J. Kinders, P. Mickey Williams, Seth M. Steinberg, Paul M. McGregor, William D. Walsh, Michele G. Mehaffey, Chih-Jian Lih, Deborah E. Allen, Jiuping Ji, Alice P. Chen, Ahrim Youn, Peter M. Szabo, Robert J. Morgan, Miguel A. Villalona-Calero, Michael J. Naughton, David R. Gandara, Daniel M. Sullivan, Gini F. Fleming, Amit M. Oza, Shivaani Kummar
Supplemental Figure S2. PAR levels in patient PBMC samples. Data shown in dark red are from patients who reported deleterious BRCA mutations, data shown in dark blue are from patients reporting wildtype BRCA status, and data in grey are from patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46eb04a4b1e5f8c650779161c0112e8a
https://doi.org/10.1158/1078-0432.22461260.v1
https://doi.org/10.1158/1078-0432.22461260.v1
Autor:
Daniel M. Sullivan, Richard M. Lush, Anthony M. Neuger, Christine E. Simonelli, Beth L. Maddox, Karen K. Fields, James S. Partyka, Teresa L. Field, Jongphil Kim, Jana L. Dawson, Steven C. Goldstein, Janelle B. Perkins
PDF file - 64K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2081e232dfa721a1f0c09972e6a65bb7
https://doi.org/10.1158/1078-0432.22445453
https://doi.org/10.1158/1078-0432.22445453
Autor:
Anthony W. Tolcher, Johann S. de Bono, Daniel M. Sullivan, Michelle D. Garrett, Martin O. Leach, Nandita M. deSouza, Karen Swales, Simon P. Heaton, Shaun Decordova, Ruth Riisnaes, Lisa Lupinacci, Robert A. Beckman, Ernestina Tetteh, Liliana Delgado, Richard Baird, David Olmos, Kyriakos P. Papadopoulos, Ivy Fearen, Andrea Biondo, Nina Tunariu, Amita Patnaik, Li Yan, Timothy A. Yap
Purpose: Multiple cancers harbor genetic aberrations that impact AKT signaling. MK-2206 is a potent pan-AKT inhibitor with a maximum tolerated dose (MTD) previously established at 60 mg on alternate days (QOD). Due to a long half-life (60–80 hours)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::371b991de3bf1445c0c528ebbb3b29a7
https://doi.org/10.1158/1078-0432.c.6523710.v1
https://doi.org/10.1158/1078-0432.c.6523710.v1
Autor:
Pamela N. Munster, Daniel M. Sullivan, Anthony Neuger, Richard Lush, Frederick A. Hausheer, Sem Bastien, Douglas Marchion, Elona Bicaku, Ronald C. DeConti, Jana Dawson, Adil I. Daud
Supplementary Data from Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d9697e5388a426a347a91ff8cd34505
https://doi.org/10.1158/1078-0432.22440090
https://doi.org/10.1158/1078-0432.22440090
Autor:
Daniel M. Sullivan, William S. Dalton, Taiga Nishihori, Christopher L. Cubitt, Jongphil Kim, Juan A. Gomez, Jana L. Dawson, Alexis A. Bauer, Yan Cui, Joel G. Turner
High-dose chemotherapy with melphalan followed by autologous transplantation is a first-line treatment for multiple myeloma. Here, we present preclinical evidence that this treatment may be significantly improved by the addition of exportin 1 inhibit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::716ac27e67b86cbe85e7fb1f7710f86b
https://doi.org/10.1158/0008-5472.c.6511792.v1
https://doi.org/10.1158/0008-5472.c.6511792.v1